Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Cuneo

Showing results (121-130 of 185) with videos related to

Pageof 19
Sort By:
Blood|September 24, 2005
Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocolAntonella Vitale, Anna Guarini, Cristina Ariola, et al.
British Journal of Cancer|June 19, 2019
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemiaAndrea Visentin, Laura Bonaldi, Gian Matteo Rigolin, et al.
British Journal of Haematology|June 13, 2008
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosisFrancesco Cavazzini, Jose Angel Hernandez, Alessandro Gozzetti, et al.
Leukemia & Lymphoma|November 25, 2016
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trialFrancesca R Mauro, Angelo M Carella, Stefano Molica, et al.
Cancers|February 15, 2022
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela StudyBeatrice Casadei, Lisa Argnani, Alessandro Broccoli, et al.
Blood|December 9, 2016
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitorsPatrizia Comoli, Sabrina Basso, Giovanni Riva, et al.
Blood|October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
Hematological Oncology|May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent studyFrancesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Haematologica|March 11, 2021
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patientsSilvia Ramos-Campoy, Anna Puiggros, Sílvia Beà, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Pageof 19

Showing results (121-130 of 185) with videos related to

Sort By:
Pageof 19
Blood|September 24, 2005
Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocolAntonella Vitale, Anna Guarini, Cristina Ariola, et al.
British Journal of Cancer|June 19, 2019
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemiaAndrea Visentin, Laura Bonaldi, Gian Matteo Rigolin, et al.
British Journal of Haematology|June 13, 2008
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosisFrancesco Cavazzini, Jose Angel Hernandez, Alessandro Gozzetti, et al.
Leukemia & Lymphoma|November 25, 2016
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trialFrancesca R Mauro, Angelo M Carella, Stefano Molica, et al.
Cancers|February 15, 2022
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela StudyBeatrice Casadei, Lisa Argnani, Alessandro Broccoli, et al.
Blood|December 9, 2016
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitorsPatrizia Comoli, Sabrina Basso, Giovanni Riva, et al.
Blood|October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
Hematological Oncology|May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent studyFrancesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Haematologica|March 11, 2021
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patientsSilvia Ramos-Campoy, Anna Puiggros, Sílvia Beà, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Pageof 19